secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-04-13T23:59:59+00:00
Accession:  0001493152-23-012154
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte cuts ~20% of workforce; expects $0.3M severance charges in Q2 2023
---------------------------------------------------------------------------

- Reduction in force involving approximately 20% of employees, announced April 12, 2023.
- Estimated charges of about $0.3 million for severance and benefits in Q2 2023.
- Management says cuts align with kitted product strategy and extend cash runway into 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223012154/0001493152-23-012154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223012154/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-012154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer